Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Melanoma

Free Subscription 27.10.2025 2 Am J Dermatopathol 1 Am J Surg 1 Ann Surg Oncol 1 BMC Cancer 1 Br J Dermatol 1 Cancer 1 Clin Cancer Res 3 J Am Acad Dermatol 1 J Invest Dermatol 1 Melanoma Res 2 N Engl J Med 1 Nat Med 1 Oncogene

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Dermatopathol

1. FORTAREZZA F, Ciolfi C, Scolaro F, Poputchikova A, et al
   Superficial Spreading Melanoma Combined With WNT-Activated Deep Penetrating/Plexiform Melanocytoma: Report of an Inedited Association.
   Am J Dermatopathol. 2025;47:871-873.
   PubMed        
   
   
2. DELLA MURA M, Sorino J, Colagrande A, Ingravallo G, et al
   Atypical Spitz Tumor/Spitz Melanocytoma Revealing a VIM::NTRK3 Gene Fusion: Clinicopathological Correlation of a Unique Molecular Finding.
   Am J Dermatopathol. 2025 Jul 1. doi: 10.1097/DAD.0000000000003051.
   PubMed         Abstract available
   
   

   
   Am J Surg

3. SOFIELD HE, Buchner SH, Nation RJ, Hess TN, et al
   Treatment patterns of anal melanoma in the era of immunotherapy.
   Am J Surg. 2025;250:116658.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. VAN AKKOOI ACJ
   Melanoma 2.0: Time to Move Beyond Breslow Thickness?
   Ann Surg Oncol. 2025 Oct 20. doi: 10.1245/s10434-025-18591.
   PubMed        
   
   

   
   BMC Cancer

5. HONG AM, Wang T, Carlino MS, Lo SN, et al
   Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1-5 extracranial melanoma oligometastases (AXIOM).
   BMC Cancer. 2025;25:1615.
   PubMed         Abstract available
   
   

   
   Br J Dermatol

6. MISTRY K, Bagdatoglou G, Daniels S, Lorigan P, et al
   The economic burden of melanoma in the UK: A stage-specific cost analysis underscoring the importance of prevention and early diagnosis.
   Br J Dermatol. 2025 Oct 22:ljaf393. doi: 10.1093.
   PubMed        
   
   

   
   Cancer

7. PEIPERT JD, Ganatra S, Zhao F, Lee JW, et al
   Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments.
   Cancer. 2025;131 Suppl 2.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

8. WIGGINS JM, Zhang Q, Zhang Y, Vand-Rajabpour F, et al
   Tumor microRNA signatures associate with stage II/III melanoma patient outcomes.
   Clin Cancer Res. 2025 Oct 20. doi: 10.1158/1078-0432.CCR-24-3785.
   PubMed         Abstract available
   
   

   
   J Am Acad Dermatol

9. PATHAK GN, Desai AD, Samie FH
   Evaluating immune-related adverse events associated with the novel LAG3 inhibitor relatlimab in combination treatment of malignant melanoma: A retrospective comparative pharmacovigilance analysis of the FAERS database.
   J Am Acad Dermatol. 2025 Oct 16:S0190-9622(25)03023.
   PubMed        
   
   
10. BROWN AB, Wix SN, Yip CH, Mafong K, et al
    Language barriers are associated with advanced presentation of melanoma in Hispanic patients: a retrospective case series.
    J Am Acad Dermatol. 2025 Oct 16:S0190-9622(25)03020.
    PubMed        
    
    
11. HONG AM, Lo SN, Fogarty GB, Stretch J, et al
    Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial.
    J Am Acad Dermatol. 2025;93:1251-1260.
    PubMed         Abstract available
    
    

    
    J Invest Dermatol

12. ZHOU XMM, Williams K, Will E, Jimenez-Sanchez D, et al
    PD-L1 negative macrophages associate with poor outcomes and high grade irAE development in melanoma patients receiving anti-PD-1 immunotherapy.
    J Invest Dermatol. 2025 Oct 16:S0022-202X(25)03414.
    PubMed        
    
    

    
    Melanoma Res

13. SUBRAMANIAN K, Parameswaran S, Maradani BS, Khetan V, et al
    Chromosomal 6q loss as a prognostic biomarker in Indian uveal melanoma: an OncoScan FFPE Assay study.
    Melanoma Res. 2025 Oct 17. doi: 10.1097/CMR.0000000000001067.
    PubMed         Abstract available
    
    

    
    N Engl J Med

14. CHAPMAN PB, Wolchok JD
    Changing Role of Adjuvant Therapy in Stage III Melanoma.
    N Engl J Med. 2025 Oct 18. doi: 10.1056/NEJMe2514054.
    PubMed        
    
    
15. ASCIERTO PA, Del Vecchio M, Merelli B, Gogas H, et al
    Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
    N Engl J Med. 2025 Oct 18. doi: 10.1056/NEJMoa2504966.
    PubMed         Abstract available
    
    

    
    Nat Med

16. LONG GV, Garnett-Benson C, Dolfi S, Ascierto PA, et al
    Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
    Nat Med. 2025 Oct 18. doi: 10.1038/s41591-025-04032.
    PubMed         Abstract available
    
    

    
    Oncogene

17. RIORDAN JD, Nathanson TA, Varzavand A, Hawkins AA, et al
    A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition.
    Oncogene. 2025 Oct 18. doi: 10.1038/s41388-025-03603.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.